Every week, we cut through the noise and surface opportunities that institutions are already eyeing, but with strategies tailored for retail traders. Today's setup? A defense giant that won a $22.9 billion missile contract on August 17, so recent it is not in the record backlog yet, while the stock fell 5.3% on the month.

We’ll cover:

RTX Corp owns Collins Aerospace, Pratt and Whitney, and Raytheon: the engines under commercial jets and the interceptors that defend airspace. On July 23 it reported a quarter that should have re-rated the stock, and did not. Backlog hit a record $289 billion, up 22% year over year. Sales were $24.7 billion, up 16% organically, adjusted EPS of $1.89 rose 21%, and management raised full-year guidance twice over.

Then came the part the market has not priced. On August 17, Raytheon was awarded a seven-year, $22.9 billion contract to build Tomahawk cruise missiles for the US Navy, lifting planned output to more than 1,000 missiles a year from roughly 60. That award landed six weeks after the June 30 backlog snapshot. It is not in the $289 billion.

So the record number you can look up is already out of date, and out of date to the upside. The order book grew by roughly 8% of the entire reported backlog in a single August afternoon, and the shares have fallen 5.3% since.

Now the honest bear case, and it got sharper today. $RTX is not cheap at 26x forward earnings, and a backlog is only worth what a supply chain can build: going from 60 missiles a year to more than 1,000 is a manufacturing problem, not a press release. And the chart has cracked, with the stock closing below its 50-day for the first time in this setup. You are buying weakness here, not strength. What you are paying for is signed work, at 9.6% below the 52-week high with an RSI of 39.

Behind the scenes:

📦 Record backlog: $289 billion of signed work, split $170 billion commercial and $119 billion defense.

🚀 The August add-on: $22.9 billion of Tomahawk work booked after the quarter closed, ramping output from about 60 units a year to over 1,000.

🎯 Book-to-bill of 2.4: $19.9 billion of Raytheon awards against $8.269 billion of segment sales in one quarter.

📈 Guidance raised twice: adjusted EPS from $6.70-$6.90 to $7.10-$7.25, organic growth from 5-6% to 8-9%.

The commercial half does quiet work the defense headlines drown out. Pratt and Whitney aftermarket sales rose 25% last quarter and Collins aftermarket rose 10%, and aftermarket is the highest-margin revenue in aerospace because it scales with flight hours.

Nobody is fighting this stock: a 1.78 analyst recommendation, under 1% short interest, 82% institutional ownership. They have simply stopped watching it.

RTX drifted sideways for a month while the order book compounded, then rolled over with the broader tape. Today it closed below its 50-day for the first time in this setup, and that deserves to be said plainly rather than buried.

Moving Averages:

✅ Below the 20-day at $217.03, so you are buying weakness rather than chasing an extension

✅ Below the 50-day at $206.75, a fresh break and the honest risk in this setup

✅ Above the 200-day at $192.69 by 6.5%, so the primary uptrend is still intact

🗝️ Key Levels:

🎯 Support: $200 (round-number line in the sand), then $192.69 (200-day)

🎯 Resistance: $206.75 (50-day), then $217.03 (20-day), then $226.88 (52-week high)

The setup: Two things argue this is a dip rather than a top. The break happened on about 60% of average volume, and it came on a third consecutive down day for the S&P 500, with no company-specific news. RSI at 39 is the most washed-out this stock has been in months, and the 14-day ATR of $4.53 puts the 52-week high about five average days of range away. But a break is a break. If it does not reclaim the 50-day, the buyers are not there.

Strengths

Weaknesses

Opportunities

Threats

Who should take it:

🟢 Conservative and income: shares only, for the 0.29 beta and 1.40% dividend.
🟡 Growth: shares plus the call below.
🔴 Aggressive: the call alone, sized as a full-loss position.

🟢 Trade Setup

🛡️ Options Play

Why this expiry, and why a plain call: the thesis pays off on two dated events, the Q3 print in late October and the midterms on November 3. November 20 is the first monthly expiration past both, and the same strike closed at $11.00 in December and $12.40 in January without buying another catalyst. On structure, the at-the-money straddle prices near 10.5% of spot over 80 days, roughly 22% annualized, and the volatility surface is flat at 27% to 28.5% across every strike that matters. Nothing is rich enough to sell, so we buy the call outright instead of financing it with a spread.

📉 Risk-Reward Breakdown - Long Nov. 20 $210 Call

💰 Payoff Table (1 contract at expiration)

How it works: the shares carry the dividend and the low-beta exposure, the call is leverage on one event window. Today's selloff cut the premium 29%, from $12.90 in the morning to $9.15 at the close, which is the one clean benefit of buying weakness. If RTX merely returns to its 52-week high by November 20, the call earns many times what the shares would, and if October disappoints the loss stops at $915.

^{(Quotes as of the Sep 1 close, 15-min delayed feed - verify with live brokerage prices. The November $210 settled $8.55 bid against a $9.15 ask.)}

The 50-day was our risk line and it broke today, so we move it down rather than pretend it held: a decisive close below $200 says the buyers never showed up and this trade is wrong. That is about 2.5% below here and it sits above the 200-day, so it triggers before the primary trend is in question. On the option there is nothing to manage: the $915 debit is the max loss, which is why we chose defined risk into an earnings event. Size so no single trade risks more than 1% to 2% of your account.

Keep your eyes on:

$RTX will never trend on social media. It signed $19.9 billion of new defense orders in ninety days, raised its own guidance twice, then won a $22.9 billion Navy contract in August that is not yet in any backlog figure you can look up. The shares went down anyway, and today they went down some more.

That gap is the entire trade. We buy shares for the low-beta exposure and one November call for leverage into a dated catalyst window: defined risk, a premium that just got 29% cheaper, and an entry into weakness rather than a breakout chase. The chart is not clean and we are not going to pretend it is. The order book is.

✅ Buy RTX at $205.16 or better
💸 Buy the Nov. 20, 2026 $210 Call for a $9.15 net debit

We'll be watching this one closely.

Want more trade ideas like this - plus weekly options plays and breakdowns?

👉 Join the Paid Resilient Trader Newsletter

For more in-depth trading strategies and market insights, upgrade to the paid version of our newsletter.

Our paid newsletter gives you:

Stay Liquid, my friends
- The Resilient Trader